{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TNGX",
  "name": "Tango Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/TNGX/",
  "json_url": "https://frontierpicks.com/dossiers/TNGX.json",
  "status": "RECENTLY_EXITED",
  "current_conviction": "LOW",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17) into a falling price — a divergence that historically resolves toward price. Next hard data is ESMO in October.",
  "invalidation_trigger": "secondary condition: the 2026-08-04 Q2 update fails to put a dated Phase 3 initiation on the calendar, or the $100M Leerink ATM activates below the $30.00 offering price.",
  "catalyst_date": "2026-09-08",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-02",
  "invalidation_fired": true,
  "themes": [
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Vopimetostat is the renamed TNG462, an MTA-cooperative PRMT5 inhibitor aimed at MTAP-deleted cancers.",
    "Daraxonrasib and zoldonrasib are Revolution Medicines assets; Tango controls neither their labels, their supply, nor the front-line registrational design.",
    "Clinical-stage with no product revenue; collaboration revenue has been zero since the Gilead agreement concluded, so the income statement carries little signal.",
    "Share count stepped from 144,647,982 pre-offering to 162,329,210 in the 2026-06-10 424B5 to 168,380,091 in the Q2 10-Q. Vendor float figures diverge sharply.",
    "Short-interest percentages differ by denominator: 26.46% of shares outstanding versus 37.07% of float on the same vendor snapshot.",
    "Vendor 52-week ranges quote an intraday $6.25-$34.39 against $32.90 on the adjusted closing series used here; a Form 144 is a notice of intent, not a completed sale."
  ],
  "body_markdown": "## Current Thesis\n\nThe asset has not changed; the structure around it keeps deteriorating. What an investor buys here is vopimetostat — the renamed TNG462, an MTA-cooperative PRMT5 inhibitor — layered onto Revolution Medicines' RAS(ON) inhibitors to build a chemotherapy-free front-line regimen in MTAP-deleted, RAS-mutant pancreatic cancer, funded by roughly $1.0 billion of cash, cash equivalents and marketable securities at 2026-06-30 (Form 10-Q filed 2026-08-11).\n\nPrior coverage named the loss of the $26.00 post-offering shelf as the structural failure to watch. It happened on the week ended 2026-08-14 (weekly close $25.60) and extended the following week (weekly close $23.88 on 08-21, with a $23.15 intraday low on 08-20). The 2026-08-24 close of $24.51 sits 25.5% under the $32.90 52-week high on the adjusted closing series and beneath the $30.00 at which the June underwritten placement cleared. RSI(14) on that series reads 22.7 — an oversold print inside a downtrend, which describes exhaustion rather than a reversal.\n\nThe narrative is **saturated**. The attention event is dated and two and a half months behind the tape — twelve retail-facing wire items clustered 2026-06-08 to 2026-06-29 around a 34.1% single session on the first combination data. Everything since has been sell-side marking rather than new participants: seven target actions from 2026-06-09 through 2026-08-18, every one a raise or bullish initiation, against a price moving the other way. What separates this from a failed narrative is that the efficacy claim has not been contradicted and has a dated re-test at ESMO, 23–27 October.\n\n## Bull Case\n\n- **The 2026-06-08 dataset remains the strongest disclosed in the class.** At a 2026-05-28 cutoff, 12 response-evaluable MTAP-deleted PDAC patients on vopimetostat plus daraxonrasib produced 11 objective responses (9 confirmed), 90% six-month PFS, 100% disease control, median PFS not reached. The zoldonrasib arm: 27 evaluable, 52% ORR (14/27, 10 confirmed), 74% six-month PFS. No discontinuations for adverse events, no related Grade 4 or 5 events.\n- **A second tumour type read out 2026-08-11.** The Q2 update disclosed a 100% ORR in the MTAP-deleted, RAS-mutant NSCLC cohort. The release summary did not restate that denominator, which caps what the figure supports.\n- **Balance sheet covers a registrational programme.** Roughly $1.0 billion in cash, cash equivalents and marketable securities at 2026-06-30, after the June deal settled at 21,166,676 common shares for $690.0M gross and $651.4M net plus 1,833,395 pre-funded warrants, underwriter option taken in full.\n- **The backbone is inside the agency.** Revolution Medicines' daraxonrasib NDA in previously treated metastatic PDAC was accepted 2026-07-22 under the FDA Commissioner's National Priority Voucher pilot, with no target action date published. RVMD's 2026-08-05 Q2 release reported the expanded-access programme had distributed drug on behalf of more than 2,000 patients, and Breakthrough Therapy designation in previously treated KRAS non-G12C metastatic NSCLC.\n- **A large short base is mechanically constrained.** The most recent vendor snapshot (stockanalysis.com, last updated 2026-08-25) shows 44.61M shares short, 26.46% of 168.61M shares outstanding and 37.07% of float, with 16.66 days to cover. Against 42,720,390 at the 2026-07-15 settlement, that is a position that has grown rather than covered — raw material for a violent reaction to a clean ESMO print.\n- **Commercial hiring ahead of a filing.** Fatma Ocak was appointed Chief Commercialization Officer effective 2026-08-17. Company commentary places finalisation of the front-line Phase 3 design in 2H 2026. That is an intention with no NCT number attached.\n\n## Bear Case\n\n- **Issuance capacity was installed into weakness.** A prospectus for up to $400M of common stock was filed 2026-08-11, weeks after the $690.0M gross June placement at $30.00 and with the shares trading below that price. Any prints under that programme happen beneath where the last institutional book cleared.\n- **Burn is widening with revenue at zero.** Q2 2026 net loss $55.3M against $45.5M in Q1 2026. Collaboration revenue has been nil since the Gilead agreement concluded.\n- **The sell-side book is uniformly long and has not yet blinked.** Published targets span $35 to $68 — HC Wainwright raised to $68 on 2026-08-18, Guggenheim raised to $35 on 2026-08-12. That spread on the same asset is an unresolved argument rather than a consensus, and no house has cut since 2026-06-09.\n- **Two of the three drugs in the thesis belong to someone else.** Daraxonrasib and zoldonrasib are Revolution Medicines assets. Tango controls neither their labels, their supply, nor the front-line registrational design.\n- **No dated registrational start exists.** The 2026-08-11 update committed to expanded ESMO data and a 2H 2026 Phase 3 design decision without an initiation date. If ESMO passes with data but no trial start, the equity has no scheduled resolution into 2027.\n- **The move is round-tripping.** From the 06-08 session that added 34.1%, the shares have given back to a 2026-08-24 close of $24.51. The three-month price change is +22.3%, the residue of a June peak far above that.\n\n## Setup & Price Structure\n\nThe $26.00 shelf is now overhead resistance, lost on the 08-14 weekly close of $25.60 and confirmed by $23.88 on 08-21. The 06-08 gap has been essentially filled: the $23.15 low on 08-20 sits inside the pre-data range. The 2026-08-24 close of $24.51 is a bounce off that low without a reclaim of anything — $26.00 and then $30.00 are the two levels that would mark a genuine repair.\n\nPositioning observables, stated as observables: retail-facing wire coverage clustered into a three-week window ending 2026-06-29 and has not renewed; the company sold $690.0M of stock into the June strength and then filed for $400M more on 2026-08-11; short interest stands at 44.61M shares on the latest vendor snapshot with 16.66 days to cover, above the 15.3 recorded at the 2026-07-15 settlement; insider sales continue on the 2025-10-27 10b5-1 plan, with a 2026-08-03 Form 144 noticing 81,000 shares against a prior 27,000-per-month cadence. A Form 144 is a notice of intent, not a completed sale.\n\nRSI(14) at 22.7 on the 2026-08-24 close is the deepest oversold reading of this leg on the adjusted series. Oversold readings in a downtrend that has already broken two reference levels resolve either into a base or into a further leg; the base has not formed, because no weekly close has yet reclaimed $26.00.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-26 (est.)** — FINRA dissemination of the 2026-08-14 short-interest settlement. First clean reading on whether the short base kept building through the loss of $26.00.\n- **~2026-09-01 (est.)** — Form 4 for the next monthly tranche under the 2025-10-27 10b5-1 plan, due within two business days of execution.\n- **2026-09-08** — ESMO Congress 2026 late-breaking abstract deadline per congress guidance. Which route the combination data takes governs how late the data cut can be relative to the 2026-05-28 cutoff behind the June release.\n- **~2026-09-10 (est.)** — dissemination of the 2026-08-31 short-interest settlement.\n- **2026-10-23 (outside the window, named for context)** — ESMO Congress 2026 opens at IFEMA Madrid, running 23–27 October. Nothing before it resolves the efficacy question.\n\n## Elapsed catalysts\n\n- **Window open, undated** — possible FDA action on daraxonrasib under the CNPV pilot; NDA accepted 2026-07-22 with no target action date published. *(passed 35d ago)*\n\n## What Would Change Our Mind\n\nThe structural break already happened; what is still open is whether the June data move round-trips in full. A weekly close below $23.00 takes out the 08-20 low of $23.15 and completes that round-trip, which would mean the market is pricing the 11-of-12 PDAC response data at approximately zero incremental value. That is the gradeable condition.\n\nThree non-price conditions would do the same work. First, the 2026-09-08 late-breaking abstract deadline passing with no company-confirmed ESMO presentation slot — the 2026-08-11 release committed to the venue, so silence past that date is information. Second, shares printing under the $400M programme at levels beneath the $30.00 June placement price, which would show management valuing capital above the marginal share price. Third, the first sell-side reduction from the six houses that have raised or initiated since 2026-06-09; the anchor for the whole group has not yet been reset downward.\n\nWhat would repair it: a weekly close back above $26.00, or an ESMO dataset that holds the response rate at a larger denominator with a dated Phase 3 initiation attached.\n\n## Correlation Notes\n\nThe tightest linkage is to Revolution Medicines. Both drugs in the disclosed combination arms are RVMD assets, and an FDA action on daraxonrasib sets the comparator any randomized front-line study must beat. RVMD headlines move TNGX independently of anything Tango itself files.\n\nSecond-order: the name trades with small-cap clinical biotech beta and with the risk appetite that funds $690M single-day placements. The June raise cleared at $30.00 inside a window when that appetite was present; the $400M shelf filed 2026-08-11 tests whether it still is.\n\nThird: the MTA-cooperative PRMT5 class has multiple large-cap entrants, and ESMO is a shared venue. A competitor disclosure during the 23–27 October window is a same-day risk to the differentiation argument, independent of what Tango presents.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-25T04:16:34+00:00",
  "last_synthesized": "2026-08-25",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}